FDA Advises Restricting Fluoroquinolone Antibiotics Use for Certain Uncomplicated Infections

[Posted by FDA on May 12, 2016]

* Serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. 
* For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options.
* Fluoroquinolones when used systemically (i.e. tablets, capsules, and injectable) are associated with disabling and potentially permanent serious side effects that can occur together. These side effects can involve the tendons, muscles, joints, nerves, and central nervous system.

FDA Recommendations: Health care professionals should stop systemic fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course.

Source: FDA.gov